




1. Sun and its affiliates or any entities acting on their behalf (collectively "Sun and Affiliates") agree not to sell, attempt to sell or offer for sale any product containing oxaliplatin until February 17, 2011.
2. Sanofi agrees not to seek any injunctive relief against Sun and Affiliates until February 15, 2011.
3. If a further stipulation, extending the terms of this stipulation, is not entered into by Sanofi and Sun by the end of the business day on February 14, 2011, then, starting on February 17, 2011, Sun will not be constrained by this stipulation from selling, attempting to sell or offering for sale any product containing oxaliplatin and, starting on February 15, 2001, Sanofi will be free to seek injunctive relief against Sun and Affiliates.
4. Sanofi and Sun and Affiliates retain any and all of their legal or equitable remedies and defenses.


We hereby consent to entry of this Order:

By:

  
\_\_\_\_\_  
Dominick A. Conde, Esq.  
FITZPATRICK, CELLA, HARPER &  
SCINTO  
1290 Avenue of the Americas  
New York, NY 10104-3800  
Phone: (212) 218-2100  
Facsimile: (212) 218-2200

Counsel for Sanofi-Aventis U.S. LLC, Sanofi-Aventis, and Debiopharm S.A.


By:

  
\_\_\_\_\_  
Daniel P. Shapiro, Esq.  
Jenny Louise Johnson, Esq.  
KATTEN MUCHIN ROSENMAN LLP  
525 West Monroe Street  
Chicago, IL 60661  
Phone: (312) 902-5622  
Facsimile: (312) 577-8668

Counsel for Sun Pharmaceutical Industries, Ltd. and Caraco Pharmaceutical Laboratories, Ltd.

SO ORDERED:

2/9/11  
Date

  
\_\_\_\_\_  
Honorable Joel A. Pisano, U.S.D.J.